CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Iclusig Ponatinib Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Ibrance Resubmission Palbociclib Advanced breast cancer Reimburse with clinical criteria and/or conditions Complete
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Ibrance Palbociclib Withdrawn
HyQvia immune globulin human and recombinant human hyaluronidase Humoral immunodeficiency Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Ulcerative colitis Do not list at the submitted price Complete
Humira Adalimumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete
Humira Adalimumab ulcerative colitis Withdrawn
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete
Last Updated : May 3, 2024